Indoco Remedies informs about unaudited financial results

25 Jul 2023 Evaluate
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Indoco Remedies has informed that the Board of Directors of the Company at its Meeting held today i.e. 25t July, 2023 has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30% June, 2023 along with the Limited Review Report with unmodified opinion on the aforesaid Unaudited Financial Results. It has enclosed copies of the following: Unaudited Standalone and Consolidated Financial Results as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Limited Review Report with unmodified opinion issued by Statutory Auditors Gokhale & Sathe, Chartered Accountants; Press Release. The Board Meeting commenced today at 10.30 am and concluded at 11.30 am. 

The above information is a part of company’s filings submitted to BSE.

Indoco Remedies Share Price

328.15 -0.40 (-0.12%)
29-Apr-2024 12:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1522.15
Dr. Reddys Lab 6272.10
Cipla 1397.00
Zydus Lifesciences 961.35
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.